日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma.

MMP2 和 MMP9 作为监测贝伐单抗治疗高级别胶质瘤的候选生物标志物

Tabouret Emeline, Boudouresque Françoise, Farina Patrizia, Barrié Maryline, Bequet Céline, Sanson Marc, Chinot Olivier

Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma.

基质金属蛋白酶 2 血浆水平与接受贝伐单抗治疗的复发性高级别胶质瘤患者的疗效和生存率的关系

Tabouret Emeline, Boudouresque Françoise, Barrie Maryline, Matta Mona, Boucard Celine, Loundou Anderson, Carpentier Antoine, Sanson Marc, Metellus Philippe, Figarella-Branger Dominique, Ouafik L'houcine, Chinot Olivier